Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer

Mehmet Altan, Eric K. Singhi, Michelle Worst, Brett W. Carter, Cheuk H. Leung, J. Jack Lee, Carolyn J. Presley, Jeff Lewis, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Jianjun Zhang, Don L. Gibbons, Ara A. Vaporciyan, John V. Heymach, Frank E. Mott

Research output: Contribution to journalArticlepeer-review


Introduction: As a result of the approval of several immune checkpoint inhibitors (ICIs) for the treatment of non-small cell lung cancer (NSCLC), many older adults are being treated with ICIs. Older adults are underrepresented in most pharmaceutical clinical trials. Therapy outcomes in this population with ICIs is particularly important since, age related factors may have an influence on the immune system. Methods: We utilized the MD Anderson Cancer Center Gemini Team's Lung Cancer Database to retrospectively study patients ≥70 years of age with advanced NSCLC treated with anti-PD-(L)1 monotherapy to look at the clinical outcomes. Results: 179 patients met the inclusion criteria for this retrospective analysis. There were 106 men and 73 women. The median age of the cohort was 74.9 years, and overall survival was 20.6 months. 27.6% of all patients had an objective response to therapy. In 33 patients who had radiological progression, treatment continued beyond progression due to clinical benefit. In this group, 6 patients had subsequent improvement in radiologic assessment. Age groups were not significantly associated with differences in clinical outcomes. Conclusions: This study suggests that anti-PD-(L)1 monotherapy is effective and well tolerated among older adults with advanced NSCLC. While pseudoprogression is rare, treatment beyond progression may provide clinical benefit in a subset of patients and warrants further investigation.

Original languageEnglish (US)
Pages (from-to)236-243
Number of pages8
JournalClinical Lung Cancer
Issue number3
StatePublished - May 2022


  • Elder adults
  • Immunotherapy
  • Treatment beyond progression

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research


Dive into the research topics of 'Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this